Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3087658 | 0.83 | CYP1A2 (0.35) | TP53 | |
| SCHEMBL2357024 | 0.80 | LTA4H (0.50) | LTA4HCYP11B1CYP11B2TP53MAPT | |
| SCHEMBL3097520 | 0.79 | SLC6A4 (0.49) | MAPTSMN1; SMN2ALDH1A1CYP2D6ATM | |
| SCHEMBL3074353 | 0.79 | SLC5A2 (0.34) | CYP2D6 | |
| SCHEMBL3079805 | 0.78 | LTA4H (0.45) | LTA4HCYP11B1CYP11B2MAPTTDP1 | |
| SCHEMBL28251912 | 0.74 | LTA4H (0.72) | LTA4HCYP11B1CYP11B2TP53MAPT | |
| SCHEMBL2027109 | 0.73 | LTA4H (0.69) | LTA4HCYP11B1CYP11B2TP53MAPT | |
| SCHEMBL11161608 | 0.72 | MAPT (0.44) | LTA4HCYP11B1CYP11B2MAPTNPC1 | |
| SCHEMBL27537260 | 0.72 | LTA4H (0.53) | LTA4HCYP11B1CYP11B2TDP1L3MBTL1 | |
| SCHEMBL3079894 | 0.72 | LTA4H (0.45) | LTA4HCYP11B1CYP11B2TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207134-B2 | Fused ring spiroketal derivative and use thereof as anti-diabetic drug | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20100234609-A1 | FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2048152-A1 | FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS DRUG FOR TREATING DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234609-A1 | FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG | REN, WNK1, GCKR | LTA4H 2233/4885CYP11B1 237/4885CYP11B2 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.